Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

NEXT STORY
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
PREV STORY
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML

Company’s Primary Development Focus is Non-Covalent Reversible BTK-Inhibitor SNS-062 Sunesis to Host Conference Call ...

author_avatar
NASDAQ Market News

Following Azedra’s Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA); U.S. Promotion ...

author_avatar
NASDAQ Market News

Esoteric Testing Market Is Expected to Reach $66.21 Billion by 2030: Says AMR

author_avatar
NASDAQ Market News